Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Dispensing compounded copies of brand-name drugs that are not on the FDA shortage list Offering large quantity "wholesale" vials without patient-specific prescriptions Selling peptides with no FDA-approved analog (BPC-157, TB-500, CJC-1295) under the label of "compounding" Providing no COA or offering only an in-house potency test rather than a third-party accredited result Lacking a clinical pharmacist available by phone to answer prescriber questions about stability, compatibility, or dosing The FDA's 2023 report on inspections of 503A pharmacies found that 60% of pharmacies inspected had at least one deficiency under USP , and 23% had deficiencies significant enough to prompt a Form 483 observation
Avoid alcohol during dose escalation when your body is still adjusting and GI side effects are at their peak
Limited-time discounts and special offers may be available on select items.
The FDA labeling documents gastrointestinal adverse effects broadlyincluding nausea (occurring in 1544% of patients depending on dose and indication), vomiting, diarrhea, abdominal pain, and constipation
